<html>
  <head>
    <title>Pathways | Oral contraceptives and venous thromboembolic risks</title>
  </head>
  <body>
    <h2>Oral contraceptives and venous thromboembolic risks</h2>
    <h4><a class='ajax' href='/specializations/22'>Obstetrics Gynecology</a></h4>
    <table class="table">
      <thead>
        <tr class='h1'>
          <th width="20%">Brand</th>
          <th width="15%">Estrogen</th>
          <th width="25%">Progestin</th>
          <th width="10%">Costs[1]</th>
          <th width="15%">Adjusted Annual relative clot risk vs. non use (95% CI)§</th>
          <th width="15%">Adjusted Annual relative clot risk vs. Levonorgestrel-containing pills§§</th>
        </tr>
      </thead>
      <tbody>
        <tr class='h2'>
          <td colspan="6">Lower risk birth control pills</td>
        </tr>
        <tr class='h3'>
          <td colspan="6">Progesterone-only pills (lowest venous thromboembolic risk)</td>
        </tr>
        <tr>
          <td>Micronor<sup>R</sup> 28</td>
          <td>-</td>
          <td>norethindrone 0.35 mg</td>
          <td>$19.37</td>
          <td>0.6 (03-1.1)</td>
          <td></td>
        </tr>
        <tr class='h3'>
          <td colspan="6">Levonorgestrel-containing combined estrogen-progestin pills</td>
        </tr>
        <tr>
          <td>Alesse<sup>R</sup> 21+28</td>
          <td>20 mcg</td>
          <td>levonorgestrel 0.1 mg</td>
          <td>$15.95</td>
          <td>2.2 (1.7-2.8)</td>
          <td>-</td>
        </tr>
        <tr>
          <td>Aviane 21+ 28</td>
          <td>20 mcg</td>
          <td>levonorgestrel 0.1 mg</td>
          <td>$10.52</td>
          <td>2.2 (1.7-2.8)</td>
          <td>-</td>
        </tr>
        <tr>
          <td>Min-Ovral<sup>R</sup> 21+28</td>
          <td>30 mcg</td>
          <td>levonorgestrel 0.15 mg</td>
          <td>$15.95</td>
          <td>2.2 (1.7-2.8)</td>
          <td></td>
        </tr>
        <tr>
          <td>Portia<sup>R</sup> 21+28</td>
          <td>30 mcg</td>
          <td>levonorgestrel 0.15 mg</td>
          <td>$10.52</td>
          <td>2.2 (1.7-2.8)</td>
          <td></td>
        </tr>
        <tr>
          <td>Seasonale / Seasonique<sup>R</sup></td>
          <td>30 mcg</td>
          <td>levonorgestrel 0.15 mg</td>
          <td>$19.80</td>
          <td>2.2 (1.7-2.8)</td>
          <td>-</td>
        </tr>
        <tr>
          <td>Triquilar<sup>R</sup> 21+28</td>
          <td>30/40/30 mcg</td>
          <td>levonorgestrel 0.05/0.075/0.125 mg</td>
          <td>$15.51</td>
          <td>2.3 (1.9-2.8)</td>
          <td>-</td>
        </tr>
        <tr class='h3'>
          <td colspan="6">Norethindrone-containing combined estrogen-progestin pills</td>
        </tr>
        <tr>
          <td>Brevicon<sup>R</sup> 0.5/35 (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 0.5 mg</td>
          <td>$12.26</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Brevicon<sup>R</sup> 1/35 (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 1 mg</td>
          <td>$12.26</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Loestrin 1.5/30 (21+28)</td>
          <td>30 mcg</td>
          <td>norethindrone acetate 1.5 mg</td>
          <td>$14.14</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Minestrin 1/20 (21+28)</td>
          <td>20 mcg</td>
          <td>norethindrone acetate 1 mg</td>
          <td>$14.14</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Ortho<sup>R</sup> 0.5/35 (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 0.5 mg</td>
          <td>$19.37</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Ortho<sup>R</sup> 1/35 (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 1 mg</td>
          <td>$19.37</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Ortho<sup>R</sup> 7/7/7 (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 0.5/0.75/1 mg</td>
          <td>$19.37</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr>
          <td>Synphasic<sup>R</sup> (21+28)</td>
          <td>35 mcg</td>
          <td>norethindrone 0.5/1 mg</td>
          <td>$11.27</td>
          <td>1.6 (0.8-2.9)</td>
          <td>0.8 (0.4-1.6), NS</td>
        </tr>
        <tr class='h3'>
          <td colspan="6">Norgestimate- containing combined estrogen-progestin pills</td>
        </tr>
        <tr>
          <td>Cyclen<sup>R</sup> 21+28</td>
          <td>35 mcg</td>
          <td>norgestimate 0.25 mg</td>
          <td>$19.37</td>
          <td>2.6 (2.2-3.0)</td>
          <td>1.2 (0.9-1.6), NS</td>
        </tr>
        <tr>
          <td>Tri-Cyclen (21+28)</td>
          <td>35 mcg</td>
          <td>norgestimate 0.18/0.215/0.25 mg</td>
          <td>$19.37</td>
          <td>2.6 (2.2-3.0)</td>
          <td>1.2 (0.9-1.6), NS</td>
        </tr>
        <tr>
          <td>Tri-Cyclen Lo (21)</td>
          <td>25 mcg</td>
          <td>norgestimate 0.18/0.215/0.25 mg</td>
          <td>$13.18</td>
          <td>2.6 (2.2-3.0)</td>
          <td>1.2 (0.9-1.6), NS</td>
        </tr>
        <tr>
          <td>Tri-Cyclen Lo (28)</td>
          <td>25 mcg</td>
          <td>norgestimate 0.18/0.215/0.25 mg</td>
          <td>$13.18</td>
          <td>2.6 (2.2-3.0)</td>
          <td></td>
        </tr>
        <tr class='h2'>
          <td colspan="6">Higher risk birth control pills</td>
        </tr>
        <tr>
          <td>Diane<sup>R</sup>-35 (acne)</td>
          <td>35 mcg</td>
          <td>cyproterone acetate 2 mg</td>
          <td>$31.52</td>
          <td>4.1 (3.4-5.0)</td>
          <td>2.1 (1.5-3.0), p&lt;.001</td>
        </tr>
        <tr>
          <td>Apri<sup>R</sup>21+28</td>
          <td>30 mcg</td>
          <td>desogestrel 0.15 mg</td>
          <td>$9.93</td>
          <td>4.2 (3.6-4.9)</td>
          <td>2.2 (1.7-3.0), p&lt;.001</td>
        </tr>
        <tr>
          <td>Linessa<sup>R</sup> 21+28</td>
          <td>25 mcg</td>
          <td>desogestrel 0.1/0.125/0.15 mg</td>
          <td>$15.58</td>
          <td>4.2 (3.6-4.9)</td>
          <td>2.2 (1.7-3.0), p&lt;.001</td>
        </tr>
        <tr>
          <td>Marvelon<sup>R</sup> 21+28</td>
          <td>30 mcg</td>
          <td>desogestrel 0.15 mg</td>
          <td>$16.44</td>
          <td>4.2 (3.6-4.9)</td>
          <td>2.2 (1.7-3.0), p&lt;.001</td>
        </tr>
        <tr>
          <td>Ortho-Cept<sup>R</sup> (21+28)</td>
          <td>30 mcg</td>
          <td>desogestrel 0.15 mg</td>
          <td>$19.37</td>
          <td>4.2 (3.6-4.9)</td>
          <td>2.2 (1.7-3.0), p&lt;.001</td>
        </tr>
        <tr>
          <td>Yasmin<sup>R</sup> 21+28</td>
          <td>30 mcg</td>
          <td>drospirenone 3 mg</td>
          <td>$12.53</td>
          <td>4.5 (3.9-5.1)</td>
          <td>2.1 (1.6-2.8), p&lt;.001</td>
        </tr>
        <tr>
          <td>Yaz<sup>R</sup> 28</td>
          <td>20 mcg</td>
          <td>drospirenone 3 mg</td>
          <td>$16.03</td>
          <td>4.8 (3.2-7.3)</td>
          <td>2.1 (1.6-2.8), p&lt;.001</td>
        </tr>
        <tr>
          <td>Ovral<sup>R</sup></td>
          <td>50 mcg</td>
          <td>d-norgestrel 0.25 mg</td>
          <td>discontinued</td>
          <td>3.5 (2.5-5.1)</td>
          <td>N/A</td>
        </tr>
        <tr class='h2'>
          <td colspan="6">Unknown risk level - no large scale studies</td>
        </tr>
        <tr>
          <td>Demulen<sup>R</sup> 30 (21+28)</td>
          <td>30 mcg</td>
          <td>ethynodiol diacetate 2 mg</td>
          <td>$13.39</td>
          <td colspan="2">N/A (sometimes classified as lower risk)</td>
        </tr>
      </tbody>
    </table>
    <p>*Lidegaard et al. BMJ 2011; 343: d6423, ; based on full population data for Denmark, 2001-2009; 8 million women-years of exposure</p>
    <p>¶US FDA Drug Safety communication: updated information about the risks of blood clots in women taking birth control pills containing drospirenone,(4-10-2012), available at: www.fda.gov/Drugs/DrugSafety/ucm299305.htm</p>
    <p> **Lidegaard et al. BMJ 2011; 343: d6423 rates derived from Table 1, crude incidence per 10,000 women-years</p>
    <p>§adjusted for age, year and education levels</p>
    <p>[1] Costs are approximate monthly costs before dispensing fee (Dec 2, 2011)</p>
    <p>§§Lidegaard et al. BMJ 2011 adjusted for age, calendar year, level of education and length of use</p>
    <p>N/A = no data available</p>
    <p>Baseline clot risk for woman under 35 on no bcp: 2.2/10,000**</p>
    <p>Baseline clot risk for woman age 35-49 on bcp: 14.8/10,000**</p>
    <p>Baseline clot risk during pregnancy (age not specified): 7-27/10,000¶</p>
    <p>baseline clot risk, early postpartum (age not specified): 40-65/10,000¶</p>
  </body>
</html>
